Clinical trial · Observational
Biomarkers of Cancer-Associated Myositis
Plasma Membrane Antigens as Trigger in Cancer-associated Myositis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project is about dermatomyositis (DM), an autoimmune disease characterized by inflammation in the skeletal muscles and skin. Patients with DM have an increased risk of cancer, with a cancer incidence between 5.5% and 42%. Cancers in these patients are one of the leading causes of death. Some myositis-specific autoantibodies have been discovered and some of them are associated with cancer development. However, DM patients negative for all the known autoantibodies can also develop cancer. The Investigator hypothesized that antibodies against plasma membrane antigens and soluble immune checkpoints can be responsible for the association between cancers and autoimmunity. Therefore, the present study aimed to identify novel antigens and immunological pathways in patients with DM with cancer versus patients with DM without cancer, to identify those patients who need cancer screening. The Investigators focus on soluble immune checkpoint molecules and autoantibodies directed against plasma membrane antigens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dermatomyositis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- DM without cancer
- description
- Patients with DM who do not have cancer at diagnosis and in the 3-year follow-up period
- label
- DM with cancer
- description
- Patients with DM who have cancer at diagnosis or in the 3-years before or after DM diagnosis
- label
- Healthy controls
- description
- Subjects without known cancer, autoimmune diseases and infections
Primary outcomes (2)
- measure
- Identification of autoantibodies against surface proteins in patients with dermatomyositis (DM) with and without cancer.
- timeFrame
- At enrollement
- description
- Serum samples from patients with DM with and without cancer will be tested for their ability to bind various cell lines surface antigens through immunofluorescence assays on live cells. Median fluorescence intensity will be evaluated. These analyses will determine whether there are differences in the levels of autoantibodies between the serum samples from patients with and without cancer. Potential autoantigens will be identified by immunoprecipitation of cell lysates with sera followed by mass spectrometry.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 40 years. * Diagnosis of DM. * Informed Consent Exclusion Criteria: * Chemotherapy at the time of the peripheral venous blood draw. * Therapy with biologic drugs at the time of the peripheral venous blood draw. * Necrotizing autoimmune myopathy.
References
Publications (0)
Data not yet available